178 Results for "

AK

" in MedChemExpress (MCE) Product Catalog:
Products (178)

178 Results for "AK" in MCE Product Catalog:

42
42 Publications Verification
Cat. No.: HY-119240
CAS No.: 324759-76-4
Purity:  99.05%
Target:  

PERK Autophagy

Research Areas:  

Neurological Disease Cancer

CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-16691
CAS No.: 420831-40-9
Target:  

Sirtuin

Research Areas:  

Neurological Disease

AK-7 is a selective cell- and brain-permeable SIRT2 inhibitor, with an IC50 of 15.5 μM.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-138794
CAS No.: 2417089-74-6
Purity:  99.60%
Research Areas:  

Cancer

XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7. XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub, thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7-nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin. XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC-mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer, neuroblastoma, and coronavirus infections .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-109142
CAS No.: 1422500-60-4
Purity:  95.51%
Synonyms: AK0529; RO-0529
Target:  

RSV

Research Areas:  

Infection

Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-103161
CAS No.: 1188890-28-9
Purity:  99.64%
Target:  

Adenosine Kinase

Research Areas:  

Inflammation/Immunology

ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC50=1.7 nM).
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-112482A
CAS No.: 2624336-92-9
ABT-702 hydrochloride is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 hydrochloride shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 hydrochloride attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 hydrochloride shows analgesic and anti-inflammatory effects in vivo. ABT-702 hydrochloride can be used for diabetic retinopathy research .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-112482
CAS No.: 214697-26-4
ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114258
CAS No.: 1919888-06-4
Purity:  99.48%
Synonyms: AK-01
Target:  

Aurora Kinase Apoptosis

Research Areas:  

Cancer

LY3295668 (AK-01) is a highly specific and orally active inhibitor of Aurora-A kinase with a Ki values for AurA and AurB of 0.8 nM and 1038 nM respectively. LY3295668 can effectively inhibit the autophosphorylation of AurA, induce mitotic arrest and apoptosis. LY3295668 avoids the formation of polyploids related to AurB inhibition. LY3295668 can be used for the study of small cell lung cancer .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148813
CAS No.: 2984506-77-4
Purity:  99.73%
Target:  

PROTACs STAT

Research Areas:  

Cancer

AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC50 of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18955
CAS No.: 1207293-36-4
Research Areas:  

Cancer

BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81190
Synonyms: p-PERK(Thr980); PERK(Phospho Thr980); PERK(Phospho T980); mo(Thr980)/hu (Thr982)/rat (Thr974); HRI; HsPEK; Pancreatic eIF2-alpha kinase; PEK; PRKR like endoplasmic reticulum kinase; WRS; DKFZp781H1925; EC 2.7.11.1; EIF2AK3; Eukaryotic translation initiation factor 2 alpha kinase 3; Heme regulated EIF2 alpha kinase.

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF, FC

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99675
CAS No.: 2428381-53-5
Synonyms: AK112

Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99117
CAS No.: 2394841-59-7
Synonyms: AK104

Target:  

PD-1/PD-L1 CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99706
CAS No.: 2428381-55-7
Synonyms: AK 117

Research Areas:  

Cancer

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99108
CAS No.: 2350298-92-7
Synonyms: AK-105

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117393
CAS No.: 137592-43-9
Purity:  98.95%
Research Areas:  

Cancer

Bisindolylmaleimide III is a protein kinase C (PKC) inhibitor with IC50 values of 0.26, 5.7, and 6 μM against PKCα, PKCδ, and PKCμ, respectively. Bisindolylmaleimide III also exhibits inhibitory activity against other off-targets, with IC50 values of 0.17, 1, and 2 μM against SLK, adenosine kinase (AK), and CDK2, respectively; its Ki for NQO2 is 16.5 μM. Bisindolylmaleimide III selectively binds to activated Rsk1 following EGF stimulation, and serves as a tool for detecting the activation status of intracellular Rsk1 and PKCα, as well as for functional analysis of SLK. Bisindolylmaleimide III can be used in studies of signal transduction and colorectal cancer .
loading...
    loading...
Cat. No.: HY-169179
CAS No.: 2984505-88-4
Target:  

PROTACs STAT

Research Areas:  

Cancer

AK-1690 is a selective PROTAC degrader targeting STAT6 (DC50=1 nM) with a Ki of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc. .
loading...
    loading...
Cat. No.: HY-169182
CAS No.: 2982851-09-0
Research Areas:  

Cancer

AK-068 is a high-affinity and selective STAT6 ligand, with a Ki of 6 nM. AK-068 demonstrates at least >150- and >85-fold binding selectivity over STAT5A (Ki >1 μM) and STAT5B (Ki >500 μM) proteins, respectively. AK-068 is a ligand for target protein for PROTAC, can be used for synthesis of PROTACs .
loading...
    loading...
Cat. No.: HY-P991636

Research Areas:  

Inflammation/Immunology

AK006 is a humanized IgG1 monoclonal antibody agonist targeting Sialic acid-binding immunoglobulin-like lectin6 (Siglec-6). AK006 potently inhibits IgE-mediated human mast cell activation. AK006 can be used for inflammatory diseases like chronic urticaria (CU) and asthma research .
loading...
    loading...
Cat. No.: HY-P99371
CAS No.: 2283348-97-8
Synonyms: AK002; Antolimab

Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
loading...
    loading...